Stability and safety key factors of the oncolytic protoparvovirus H-1 from manufacturing to human application.

Frehtman, Veronika; Wohlfarth, Daniel; Müller, Marcus; Krebs, Ottheinz; Leuchs, Barbara

Frehtman, Veronika; Wohlfarth, Daniel; Müller, Marcus; Krebs, Ottheinz; Leuchs, Barbara.

Afiliação

Frehtman V; German Cancer Research Center, Tumor Virology, Im Neuenheimer Feld 280, 69120, Heidelberg, Germany.
Wohlfarth D; German Cancer Research Center, Tumor Virology, Im Neuenheimer Feld 280, 69120, Heidelberg, Germany.
Müller M; German Cancer Research Center, Tumor Virology, Im Neuenheimer Feld 280, 69120, Heidelberg, Germany.
Krebs O; German Cancer Research Center, Tumor Virology, Im Neuenheimer Feld 280, 69120, Heidelberg, Germany.
Leuchs B; German Cancer Research Center, Tumor Virology, Im Neuenheimer Feld 280, 69120, Heidelberg, Germany. B.Leuchs@dkfz.de.

Appl Microbiol Biotechnol ; 107(15): 4777-4787, 2023 Aug.

Article em En | MEDLINE | ID: mdl-37209160

Assuntos

Glioblastoma; Parvovirus H-1; Terapia Viral Oncolítica; Vírus Oncolíticos; Neoplasias Pancreáticas; Humanos; Vírus Oncolíticos/fisiologia; Terapia Viral Oncolítica/métodos; Parvovirus H-1/fisiologia; Neoplasias Pancreáticas/terapia

Palavras-chave

Deactivation; Drug product; Environmental safety; Formulation; Protoparvovirus H-1PV; Stability

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Glioblastoma / Vírus Oncolíticos / Terapia Viral Oncolítica / Parvovirus H-1 Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google